Nov 1, 2018 Sanofi and Denali Therapeutics ink €1.125bn deal in neurology/inflammation Sanofi and Denali Therapeutics ink €1.125bn deal in neurology/inflammationSanofi wants to assess the potential of DNL747 in neurological diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), ... read morePublished on 2018-11-01